Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.

Johnson & Johnson, a Dividend King with a 64-year streak of annual dividend increases, took a $7 billion charge in Q3 2026 due to legal expenses from a talcum powder lawsuit and other costs. Despite this, the company increased its full-year guidance, indicating resilience and focus on long-term growth. The litigation charge, while significant, may ultimately be a positive as it could streamline J&J's focus on growth.

The company's revenues grew nearly 6% in the quarter, demonstrating that its core business remains strong, even if GAAP earnings per share declined roughly 96%. As a healthcare giant, J&J's products are often essential during economic downturns, suggesting potential long-term growth. Investors should consider the timing of the charge, as a bull market might overlook such issues, while a bear market could amplify investor concern.

Nonetheless, Johnson & Johnson's Dividend King status and resilient business indicate it remains a strong investment choice for conservative long-term dividend investors.